178 related articles for article (PubMed ID: 16648531)
1. Antidepressant therapy and C-reactive protein levels.
O'Brien SM; Scott LV; Dinan TG
Br J Psychiatry; 2006 May; 188():449-52. PubMed ID: 16648531
[TBL] [Abstract][Full Text] [Related]
2. [Selective serotonin reuptake inhibitors in major depressive disorder in children and adolescents (ratio of benefits/risks)].
Hjalmarsson L; Corcos M; Jeammet P
Encephale; 2005; 31(3):309-16. PubMed ID: 16142045
[TBL] [Abstract][Full Text] [Related]
3. Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial.
Kroenke K; West SL; Swindle R; Gilsenan A; Eckert GJ; Dolor R; Stang P; Zhou XH; Hays R; Weinberger M
JAMA; 2001 Dec; 286(23):2947-55. PubMed ID: 11743835
[TBL] [Abstract][Full Text] [Related]
4. New generation antidepressants for depression in children and adolescents: a network meta-analysis.
Hetrick SE; McKenzie JE; Bailey AP; Sharma V; Moller CI; Badcock PB; Cox GR; Merry SN; Meader N
Cochrane Database Syst Rev; 2021 May; 5(5):CD013674. PubMed ID: 34029378
[TBL] [Abstract][Full Text] [Related]
5. A functional variant in the serotonin receptor 7 gene (HTR7), rs7905446, is associated with good response to SSRIs in bipolar and unipolar depression.
Wei YB; McCarthy M; Ren H; Carrillo-Roa T; Shekhtman T; DeModena A; Liu JJ; Leckband SG; Mors O; Rietschel M; Henigsberg N; Cattaneo A; Binder EB; Aitchison KJ; Kelsoe JR
Mol Psychiatry; 2020 Jun; 25(6):1312-1322. PubMed ID: 30874608
[TBL] [Abstract][Full Text] [Related]
6. Switching Selective Serotonin Reuptake Inhibitors in Adolescents with Selective Serotonin Reuptake Inhibitor-Resistant Major Depressive Disorder: Balancing Tolerability and Efficacy.
Strawn JR; Mills JA; Croarkin PE
J Child Adolesc Psychopharmacol; 2019 May; 29(4):250-255. PubMed ID: 30810350
[No Abstract] [Full Text] [Related]
7. Effects of selective serotonin reuptake inhibitors on thyroid function in depressed patients with primary hypothyroidism or normal thyroid function.
de Carvalho GA; Bahls SC; Boeving A; Graf H
Thyroid; 2009 Jul; 19(7):691-7. PubMed ID: 19583486
[TBL] [Abstract][Full Text] [Related]
8. [Use of antidepressant drugs in schizophrenic patients with depression].
Micallef J; Fakra E; Blin O
Encephale; 2006; 32(2 Pt 1):263-9. PubMed ID: 16910628
[TBL] [Abstract][Full Text] [Related]
9. Remission with mirtazapine and selective serotonin reuptake inhibitors: a meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression.
Thase ME; Nierenberg AA; Vrijland P; van Oers HJ; Schutte AJ; Simmons JH
Int Clin Psychopharmacol; 2010 Jul; 25(4):189-98. PubMed ID: 20531012
[TBL] [Abstract][Full Text] [Related]
10. Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression.
Fava M; Rosenbaum JF; Hoog SL; Tepner RG; Kopp JB; Nilsson ME
J Affect Disord; 2000 Aug; 59(2):119-26. PubMed ID: 10837880
[TBL] [Abstract][Full Text] [Related]
11. Sertraline: a review of its use in the management of major depressive disorder in elderly patients.
Muijsers RB; Plosker GL; Noble S
Drugs Aging; 2002; 19(5):377-92. PubMed ID: 12093324
[TBL] [Abstract][Full Text] [Related]
12. Monoamine transporter gene polymorphisms and antidepressant response in koreans with late-life depression.
Kim H; Lim SW; Kim S; Kim JW; Chang YH; Carroll BJ; Kim DK
JAMA; 2006 Oct; 296(13):1609-18. PubMed ID: 17018806
[TBL] [Abstract][Full Text] [Related]
13. Long-term costs of treatment for depression: impact of drug selection and guideline adherence.
Crown WH; Treglia M; Meneades L; White A
Value Health; 2001; 4(4):295-307. PubMed ID: 11705297
[TBL] [Abstract][Full Text] [Related]
14. Use of Bayesian net benefit regression model to examine the impact of generic drug entry on the cost effectiveness of selective serotonin reuptake inhibitors in elderly depressed patients.
Shih YC; Bekele NB; Xu Y
Pharmacoeconomics; 2007; 25(10):843-62. PubMed ID: 17887806
[TBL] [Abstract][Full Text] [Related]
15. Which SSRIs most effectively treat depression in adolescents?
DeLucia V; Kelsberg G; Safranek S
J Fam Pract; 2016 Sep; 65(9):632-4. PubMed ID: 27672691
[TBL] [Abstract][Full Text] [Related]
16. Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment.
Fava M; Judge R; Hoog SL; Nilsson ME; Koke SC
J Clin Psychiatry; 2000 Nov; 61(11):863-7. PubMed ID: 11105740
[TBL] [Abstract][Full Text] [Related]
17. Algorithm-based treatment of major depression in an outpatient clinic: clinical correlates of response to a specific serotonin reuptake inhibitor and to triiodothyronine augmentation.
Agid O; Lerer B
Int J Neuropsychopharmacol; 2003 Mar; 6(1):41-9. PubMed ID: 12899735
[TBL] [Abstract][Full Text] [Related]
18. Antidepressant medication change in a clinical treatment setting: a comparison of the effectiveness of selective serotonin reuptake inhibitors.
Nurnberg HG; Thompson PM; Hensley PL
J Clin Psychiatry; 1999 Sep; 60(9):574-9. PubMed ID: 10520974
[TBL] [Abstract][Full Text] [Related]
19. Plasma serotonin levels are associated with antidepressant response to SSRIs.
Holck A; Wolkowitz OM; Mellon SH; Reus VI; Nelson JC; Westrin Å; Lindqvist D
J Affect Disord; 2019 May; 250():65-70. PubMed ID: 30831543
[TBL] [Abstract][Full Text] [Related]
20. [Interest of the use of pindolol in the treatment of depression: review].
Brousse G; Schmitt A; Chereau I; Eschalier A; Dubray C; Llorca PM
Encephale; 2003; 29(4 Pt 1):338-50. PubMed ID: 14615704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
